Prospective observational study of sirolimus as primary immunosuppression after renal transplantation

Mark D. Pescovitz, Nosratollah Nezakatgoo, Marc I. Lorber, Bjorn Nashan, Helio Tedesco-Silva, Bertram L. Kasiske, Federico J.Juarez De La Cruz, Graeme Russ, Joseph Campistol, Paul A. Keown

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

BACKGROUND.: Sirolimus (SRL) is an important component of clinical immunosuppression in renal transplantation, but few international studies have examined how this agent is used in routine practice. METHODS.: Within a large prospective pharmacoepidemiological study, 718 de novo renal graft recipients treated with SRL in 65 centers in 10 countries were monitored for up to 5 years posttransplant to compare the principal outcomes and adverse effects by treatment regimen. RESULTS.: Principal treatment regimens were SRL without a calcineurin inhibitor (33%), SRL+cyclosporine A (CsA) (33%), and SRL+tacrolimus (TAC) (34%); 18% of subjects discontinued SRL, 124/718 (17%) developed biopsy-confirmed acute rejection (BCAR), 64/718 (9%) lost their graft, and 50/718 (7%) died during follow-up. Calculated creatinine clearance was 66±26 mL/min at 2 years. The most common adverse events were hypertension, hyperlipidemia, anemia, urinary tract infections, and diabetes. BCAR was significantly lower in subjects receiving SRL+TAC (hazard ratio [HR] 0.46, P=0.009) but not significantly lower in those receiving SRL+CsA (HR 0.62, P=0.102) compared with SRL without a calcineurin inhibitor. Graft loss or death did not significantly differ between treatment groups but were associated, respectively, with deceased donor grafts (HR 3.33, P<0.001) and increased age (HR 1.04, P<0.001). No improvement was observed in patients receiving mycophenolate mofetil in any treatment combination (HR 0.80, P=0.438 for BCAR; HR 0.93, P=0.849 for graft loss; and HR 0.75, P=0.531 for death). CONCLUSIONS.: SRL is most commonly used in combination with mycophenolate mofetil, CsA, or TAC. BCAR was least common in subjects receiving SRL+TAC, but other outcomes seemed comparable between the treatment regimens in routine practice.

Original languageEnglish (US)
Pages (from-to)1010-1018
Number of pages9
JournalTransplantation
Volume88
Issue number8
DOIs
StatePublished - Oct 2009

Keywords

  • Immunosuppression
  • Kidney
  • Rejection.
  • Sirolimus
  • Transplantation

Fingerprint

Dive into the research topics of 'Prospective observational study of sirolimus as primary immunosuppression after renal transplantation'. Together they form a unique fingerprint.

Cite this